Not medical advice. Talk to your provider before using any peptide. Full disclaimer
Epithalon
Beginner tier: 5 mg, daily · 3w on / 20w off · community consensus
Also known as: Epitalon, Epithalon, Epithalone
Get an alert when FDA rules on Epithalon
Follow every legal or FDA change, Epithalon included. By default, alerts come as one weekly push that names the peptides.
Four amino acids. Ala-Glu-Asp-Gly. That sequence is epithalon (also called epitalon), a tetrapeptide studied for over two decades by Vladimir Khavinson's lab in St. Petersburg. In his 2003 study with Anisimov, female mice lived no longer on average, though maximum lifespan rose 12.3% (PMID 14501183 (opens in a new tab)). In 2025, Al-Dulaimi's group independently confirmed telomere elongation in human cell lines for the first time outside Khavinson's own team [1]. No blinded human trial has ever been published. The community uses it anyway, mostly for sleep. Pineal melatonin normalization kicks in within days, and that effect is consistent across hundreds of self-reports on r/peptides and Longecity.
What Is Epithalon?
A 2025 paper changed the conversation around this peptide. Al-Dulaimi and colleagues replicated epithalon's telomere elongation effect in human cell lines [1], confirming telomerase upregulation independent of Khavinson's lab for the first time.
Epithalon (epitalon, molecular weight 390.35 Da) is a synthetic tetrapeptide modeled after epithalamin, a pineal gland extract. It activates telomerase, the enzyme that adds TTAGGG repeats to chromosome ends. Short telomeres push cells into senescence or death. Restoring telomerase activity, at least in theory, reverses that clock.
The practical picture is more complicated. Seven of the papers sent to FDA to support compounding it described epithalamin, the pineal extract, not epithalon. FDA treats the two as different substances and found three human studies of epithalon itself (July 2026 briefing). FDA describes one of them as randomized and placebo-controlled (Ivko 2021). It was small: 40 women aged 40 to 50 took sublingual epithalon or placebo for 20 days. A urinary melatonin marker rose 1.7-fold on epithalon. The study reported no safety data and did not say whether it was blinded. A 2025 IJMS review [2] noted explicitly that safety information on this peptide is missing.
Community use tells a different story. Hundreds of users across peptide forums run 10-day cycles twice per year and report rapid sleep improvement, typically by day 3 to 5. That effect operates through pineal melatonin normalization, a faster and better-understood mechanism than telomere extension. Deeper sleep, fewer awakenings, and improved morning energy are the most reproducible outcomes. The telomere claim itself is taken largely on faith since no practical at-home marker exists; telomere testing before and after multiple cycles is the only objective route, and single-measurement variability is large.
Epithalon was on the FDA Category 2 list until its nominators withdrew it (FDA page current as of April 22, 2026), and PCAC discussed it on July 24, 2026. All current supply is research-grade.
How Epithalon Works
Telomeres are repetitive TTAGGG sequences at chromosome tips. They shorten with every cell division. When they get too short, cells stop dividing or die. Telomerase is the enzyme that rebuilds them.
Epithalon activates telomerase in cell cultures. Khavinson's 2003 paper [3] demonstrated telomere elongation in human somatic cells treated with the peptide. The 2025 replication by Al-Dulaimi's group confirmed this finding and added a new wrinkle: some cell lines showed ALT (alternative lengthening of telomeres) pathway activation rather than telomerase upregulation [1]. That second pathway is worth watching because ALT is associated with certain cancer types.
The sleep effect runs through a separate mechanism. Epithalon stimulates the pineal gland and restores normal melatonin secretion patterns. Goncharova and colleagues showed this in aging primates and rats [4]. Pineal restoration is a much faster biological response than telomere extension; it explains why sleep improves within days while telomere changes, if they occur in living humans, would take months or years to measure.
Plasma half-life is estimated at roughly 30 minutes based on tetrapeptide class pharmacokinetics. No formal human PK study has been published. Daily injection maintains exposure through repeated stimulation rather than sustained blood levels. The short-burst cycling protocol (10 days on, months off) follows the logic that telomerase activation triggers a persistent cellular process. You're kickstarting repair, not maintaining a drug level.
Epithalon Benefits
- Epithalon benefits center on telomere maintenance and sleep quality, with the sleep effect being far more reproducible in practice.
- Telomerase activation confirmed in human cell lines by two independent labs (Khavinson 2003; Al-Dulaimi 2025)[3][1]. The 2025 paper was the first replication outside Russia.
- Sleep improvement within 3 to 5 days is the most consistent community-reported effect across hundreds of users on r/peptides and Longecity. Faster onset, fewer awakenings, more deep sleep.
- In female mice injected on 5 consecutive days each month from 3 months of age, mean lifespan did not change, but the longest-lived 10% lived 13.3% longer and maximum lifespan rose 12.3% (Anisimov 2003, PMID 14501183 (opens in a new tab)). No human longevity data exists.
- Melatonin normalization through direct pineal gland stimulation (Goncharova et al.)[4], a distinct mechanism from the telomere effect that operates within days.
- Persistent post-cycle effects. Sleep benefits typically last 4 to 8 weeks after the active cycle ends, and telomere gains, if they occur, don't reverse overnight.
Epithalon: Science vs Community Consensus
Telomerase activation and telomere elongation confirmed in cell cultures (human and bovine).
Read the evidence (key study, limitations)
In female mice, mean lifespan did not change; maximum lifespan rose 12.3% (PMID 14501183 (opens in a new tab)). Al-Dulaimi et al. (2025) is the first independent Western replication: in human cell lines only, not a clinical trial. Older human data come from Khavinson's own unblinded, uncontrolled cohorts in elderly Russian populations (1990s–2000s), and several of those papers used epithalamin, a different substance (FDA, July 2026). One small placebo-controlled study (Ivko 2021: 40 women, 20 days, sublingual) raised a urinary melatonin marker 1.7-fold. A 2025 IJMS systematic overview explicitly noted "information regarding critical issues about this peptide's safety is missing." The mechanism is real. The human proof is not there yet.
Al-Dulaimi et al. (2025): "Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity." Biogerontology. First independent non-Khavinson replication. PMID 40908429 / PMC12411320.
One small placebo-controlled trial (Ivko 2021, per FDA's July 2026 briefing); it did not report blinding or safety data. No published human pharmacokinetic data. Half-life (~30 min) is an unverified class-level estimate with no published PK source. 2025 replication is in vitro only. Khavinson cohort studies lack blinding, randomization, and independent oversight. ALT pathway activation in cancer cell lines (Al-Dulaimi 2025) is a new, unresolved safety signal.
Widely used in longevity and biohacker communities.
Read the reports (what users report 4, common issues 5)
Sleep improvement is the most consistently and rapidly reported effect: typically within days 3–5. General well-being and energy also commonly reported during and after cycles. The telomere claim is taken largely on faith since there is no practical at-home marker. Community is split on cancer risk: some avoid it entirely due to the telomerase concern, others cite Khavinson's mouse data showing reduced tumor incidence.
- Sleep quality improvement: faster onset, fewer nighttime awakenings, more restorative sleep (most reproducible and rapidly appearing effect)
- Increased daytime energy and mental clarity during and shortly after the active cycle
- General sense of well-being persisting weeks after cycle ends
- Some users report improved skin texture and faster recovery over multiple yearly cycles
- No subjective marker for the primary claim: telomere lengthening is invisible without a lab test
- Research credibility concern: nearly all published data from a single lab until 2025
- Cancer risk ambiguity via telomerase activation is a genuine concern that keeps a subset of users away
- Product authenticity is hard to verify; inexpensive tetrapeptide is easily adulterated or under-dosed
- Sleep benefit is real but achievable via cheaper and better-studied means (melatonin, sleep hygiene)
Science and community agree on the telomerase mechanism and the melatonin/sleep effect. Community confidence in human anti-aging outcomes significantly exceeds what the scientific evidence supports. Khavinson's observational cohorts are treated as stronger evidence than their methodology warrants. The sleep effect is real and reproducible but operates through pineal melatonin normalization, a much faster and more modest mechanism than telomere extension. The leap from in vitro telomere data to meaningful human anti-aging benefit is unproven.
Epithalon Dosage Guide
Reconstitution is straightforward. A 10 mg vial with 2 mL bacteriostatic water gives you 5 mg/mL. For a 10 mg dose, you'd draw 100 units (the full 1 mL) from a standard insulin syringe, but that only gets half the vial. Most people add 1 mL of bac water instead. That gives 10 mg/mL; 100 units equals your full 10 mg dose from one vial.
For the 5 mg beginner dose: reconstitute with 2 mL bac water (2.5 mg/mL), draw 100 units (1.0 mL) for 2.5 mg per dose. The vial lasts four doses. Alternatively, reconstitute with 1 mL bac water (10 mg/mL) and draw 50 units (0.5 mL) for 5 mg per dose; the vial lasts two days. Option B matches the beginner protocol dose of 5 mg per day.
Swirl gently after adding water. Don't shake. Solution should be clear and colorless; discard if cloudy or you see particles.
The thing most beginners miss: you won't feel the anti-aging part working. Sleep and energy are your only real-time feedback. For objective data on telomeres, get a baseline test before your first cycle and retest after 2 to 3 completed cycles using the same lab and assay method. Single-measurement variability is large enough to mislead you otherwise.
Store lyophilized powder at room temperature for up to 6 months, or refrigerate for longer shelf life. After reconstitution, refrigerate at 2 to 8 degrees C and use within 3 to 4 weeks.
Cycling Protocol
Run 10-20 day intensive cycles, then off for 4-6 months. Effects persist long after the cycle ends. Most users do 2-3 cycles per year.
Epithalon follows Khavinson's original short-burst cycling logic: 10 days of intensive daily injection, then 4–6 months off. The rationale is that telomerase activation triggers a persistent cellular process (telomere elongation) that continues after the peptide is cleared from plasma: you are kickstarting a repair process, not maintaining a blood level. The melatonin normalization effect also appears to outlast the active cycle by weeks. Continuous daily dosing has no published support and increases cumulative exposure to a telomerase activator, which raises the theoretical cancer risk profile without demonstrable additional benefit.
- Sleep benefits fading back to personal baseline (typically 2–3 months post-cycle) is the most common trigger for scheduling the next cycle
- Telomere testing showing continued shortening despite multiple cycles may indicate non-response: reassess whether to continue
- Most users follow a calendar schedule (2×/year, spring and autumn) rather than symptom-based timing
- Running >3 cycles/year has no published support and increases theoretical telomerase exposure without evidence of additional benefit
Or use the universal Peptide Calculator for any peptide.
Epithalon Protocols by Goal
Expected: Sleep improvement within the first week. Energy and well-being during and post-cycle. Telomere effects, if real, accumulate over multiple cycles over years: not perceptible day-to-day.
Monitor: Telomere length testing (TeloYears, Life Length, RepeatDx) before starting and after 2–3 cycles is the only objective data point on the primary mechanism. Sleep wearable (Oura, Whoop, Apple Watch) is the most practical subjective response tracker.
Who Uses Epithalon?

Entrepreneur & Longevity Pioneer
Peptides are effective when used precisely.
How to Use Epithalon
- 1Step 1
Gather supplies: epithalon vial (10 mg or 25 mg), bacteriostatic water, alcohol swabs, 29 to 31 gauge insulin syringe.
- 2Clean the vial stopper with an alcohol swab
Add bacteriostatic water slowly down the side of the vial. For a 10 mg vial, 1 mL bac water gives 10 mg/mL. For a 25 mg vial, 2.5 mL gives 10 mg/mL.
- 3Swirl gently until dissolved
Do not shake. Solution must be clear and colorless.
- 4Draw your dose
For 10 mg at 10 mg/mL concentration: pull 100 units (1 mL) on the insulin syringe. For 5 mg at 5 mg/mL: pull 50 units (0.5 mL).
- 5Clean the injection site with alcohol
Abdomen (2 inches from navel) or deltoid are most common. Rotate sites over the 10-day cycle.
- 6Step 6
Pinch skin, insert needle at a 45-degree angle, inject slowly. Release skin and withdraw.
- 7Inject once daily, 30 to 60 minutes before bed
Evening timing aligns with the melatonin normalization effect.
- 8Refrigerate the reconstituted vial at 2 to 8 degrees C
Use within 3 to 4 weeks.
- 9Run 10 to 20 days active, then stop for 4 to 6 months
Most users follow a spring and autumn schedule, two cycles per year.
Alternative Routes
N/A: reference route used in all published research and community protocols
As a tetrapeptide, epithalon is destroyed by digestive enzymes: oral delivery is not viable. Use 29–31 gauge insulin syringe. Abdomen and deltoid are most common sites. Rotate sites over multi-day cycles.
Higher dose likely needed to compensate for lower mucosal absorption; no evidence-based dose established for this route
Some community reports of nasal spray use (1–2 mg/mL, 2–4 sprays per nostril 2×/day). No published data on intranasal epithalon pharmacokinetics or efficacy. Absorption through nasal mucosa for a tetrapeptide of this size is not validated. Not recommended as primary route.
Epithalon Stacking Protocols
Works With
Complementary anti-aging mechanisms: GHK-Cu targets extracellular matrix repair and gene expression modulation; epithalon targets telomere maintenance. Different biological pathways, no known pharmacokinetic interaction. Most common community longevity pairing.
GHK-Cu 1–2 mg/day SC concurrent with the epithalon active cycle
Part of community "full recovery + longevity" stack. BPC-157 for tissue healing and systemic repair; epithalon for cellular aging. Different mechanisms, widely combined in practice. No published interaction data.
BPC-157 250 mcg 2×/day + epithalon 10 mg/day before bed during active cycle
Also part of the community "kitchen sink" longevity stack (BPC-157 + TB-500 + GHK-Cu + Epithalon). TB-500 for systemic tissue repair and healing; epithalon for telomere maintenance. No published combination or interaction data.
GH secretagogue for body composition and recovery + epithalon for anti-aging. Both GH output and telomere length decline with age. Commonly paired in longevity-focused community protocols. No interaction or combination data exists.
Avoid
Epithalon normalizes endogenous melatonin production via pineal stimulation. Concurrent high-dose exogenous melatonin risks excessive sedation and may blunt the pineal feedback loop epithalon is trying to restore. Low-dose melatonin (0.3 mg) likely acceptable but unnecessary during an active cycle.
Telomerase activation directly opposes oncological treatments that target telomerase in cancer cells (e.g., BIBR 1532, imetelstat). Hard contraindication, not theoretical concern. Also contraindicated in anyone with active cancer for the same mechanistic reason.
Do not combineHow much does Epithalon cost?
Typical price
$3.31 to $5.00 per mg
Middle half of 86 US prices for 10 mg vials · read Oct 31
Free account. Not a pharmacy price: these are vials sold online, and none is an FDA-approved medicine.
Pricing updated 2026-04-09
Epithalon Side Effects
The biggest concern with epithalon isn't a side effect you'll feel. It's a theoretical risk you can't observe. Telomerase reactivation is a hallmark of cancer cell immortalization. Khavinson's rodent studies actually showed reduced tumor rates with epithalon, but Al-Dulaimi's 2025 paper found ALT pathway activation in cancer cell lines [1]. That's a new signal. Anyone with active cancer or a cancer history should treat this as a hard stop.
A 2025 IJMS systematic overview [2] stated explicitly that "information regarding critical issues about this peptide's safety is missing." The total human safety database is small, uncontrolled, and comes almost entirely from one research group.
Published side effects from Khavinson's cohort studies: none reported beyond injection site reactions. That's a limitation of the data, not proof of safety. Unblinded observational studies in elderly populations are not designed to catch adverse events with any rigor.
Community-reported effects paint a more complete picture. Injection site redness is common and expected for subcutaneous peptide administration. Rotate between abdomen and deltoid over a 10-day cycle. Redness spreading beyond the immediate injection area or lasting more than 24 hours warrants stopping.
Vivid dreams and occasionally nightmares are reported by a minority of users. This tracks with the melatonin mechanism; improved melatonin output alters REM sleep architecture. It usually settles within a few days. Dropping to 5 mg/day helps if dreams become disruptive.
Daytime drowsiness can occur, particularly if you're stacking epithalon with exogenous melatonin, magnesium, GABA, or valerian. The combination over-sedates. Reduce the dose or shift injection earlier in the evening.
Contraindications: pregnancy or breastfeeding, active cancer or cancer history, known hypersensitivity to any of the four amino acid components, autoimmune conditions (use with medical supervision only), and children or adolescents (no safety data). Immunosuppressant users need close monitoring since epithalon may modulate immune function. Anyone on chemotherapy or anti-telomerase agents (imetelstat, BIBR 1532) faces a direct mechanistic conflict.
Stop immediately if any unexplained mass or growth appears. Discontinue if cancer is diagnosed at any point during use. Stop if sleep paradoxically worsens. Do not extend cycles beyond 20 days.
Common Issues & Solutions
No sleep improvement after 7 days: product identity is the first unknown. HPLC purity (above 98% is the usual benchmark) and mass spec confirmation of the molecular weight (390.35 Da) are the tests that settle it. Ensure injection is in the evening, not morning. If product checks out, non-response to the melatonin effect is real: not everyone notices it.
Injection site redness or irritation: expected for subcutaneous peptide injections. Rotate sites between abdomen and deltoid. Redness spreading beyond the immediate injection area or lasting >24 hours warrants stopping and assessing for contamination or allergic reaction.
Vivid dreams or nightmares: reported by a minority of users, likely from enhanced melatonin output altering REM sleep architecture. Usually settles within a few days. Drop to 5 mg/day if disruptive.
Daytime drowsiness: reduce to 5 mg/day or shift injection earlier in the evening. Check for concurrent sedating supplements (melatonin, magnesium, GABA, valerian): the combination may be over-sedating.
Expecting to feel anti-aging effects: you won't. Telomere changes are cellular and invisible. Sleep and energy are the only subjective markers during a cycle. For objective data, get a telomere length test before starting and again after 2–3 cycles: understanding that single-measurement variability is large.
Ask AI about this page
Ask AI for a second opinion on Epithalon dosing and side effects
Contraindications
- Pregnancy or breastfeeding
- Active cancer or history of cancer (telomerase activation may theoretically promote tumor cell survival)
- Known hypersensitivity to Epithalon or any of its amino acid components
- Autoimmune conditions: use with caution and medical supervision
- Children and adolescents (insufficient safety data)
Drug Interactions
- Immunosuppressants: Epithalon may modulate immune function; monitor closely if on cyclosporine, tacrolimus, or similar agents
- Melatonin supplements: Epithalon normalizes endogenous melatonin; exogenous melatonin dosing may need adjustment
- Chemotherapy or anti-cancer agents: telomerase activation could theoretically interfere with treatments targeting telomerase in tumor cells
- Sedatives and sleep medications: improved melatonin output may potentiate sedative effects
Product Quality
Simple 4-amino-acid chain (Ala-Glu-Asp-Gly) that is inexpensive and straightforward to synthesize. This cuts both ways: high-purity product is cheap to make, but the low price also makes adulteration or under-dosing economically viable. Epithalon is listed as withdrawn from FDA Category 2 (FDA page current as of April 22, 2026), but no FDA rule has added it to the 503A bulks list, so compounding pharmacies cannot use it today; PCAC discussed it on July 24, 2026. All current supply remains research-grade with variable quality standards and no FDA reference standard to benchmark against.
- Identity and purity testing: HPLC reports purity (above 98% is the usual benchmark), and mass spec confirms the molecular weight (390.35 Da)
- Lot numbers: a test result applies only to the batch it names, so a report with no lot number says little about any one vial
- Independent versus in-house testing: a result from an independent lab carries more weight than an in-house analysis
- Reconstituted solution must be clear and colorless: discard immediately if cloudy or particulate
- Store lyophilized powder refrigerated; sealed room-temperature storage acceptable up to ~6 months
- After reconstitution, refrigerate at 2–8°C and use within 3–4 weeks
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| Telomere length test | Before starting (baseline), then after 2–3 completed cycles (~12–18 months) | Directional improvement from personal baseline. Single-point telomere measurements have large inter-test variability; use the same lab and assay method for baseline and follow-up. |
| Sleep tracking (wearable or diary) | Continuously: baseline before cycle, throughout active cycle, and 4–8 weeks post-cycle | Improvement over personal pre-cycle baseline: compare cycle averages, not single nights. Consumer wearables are directionally useful but not clinical-grade. |
| CBC + CMP (basic bloodwork) | Annually if running regular cycles | Not listed |
Only objective data point on the primary claimed mechanism. Optional: for users who want measurable data rather than proceeding purely on faith.
Most practical and reproducible way to gauge subjective response. Deep sleep percentage and sleep efficiency are the key metrics.
General health monitoring. Epithalon has no known effect on standard blood markers, but annual labs are good practice for regular research peptide use.
Epithalon Before and After
Initial loading phase. No noticeable external changes. Telomerase activation begins at the cellular level. Some users report improved sleep quality within the first few days due to melatonin normalization.
Mid-cycle. Sleep improvements become more consistent. Subtle increases in energy and mental clarity reported by some users. Telomere elongation processes are underway but not yet measurable.
End of active cycle. Cumulative telomerase activation reaches peak effect. Users commonly note improved sleep architecture, better recovery, and a general sense of well-being.
Effects persist after stopping. Telomere length gains from the active cycle are maintained. Melatonin normalization continues. No injections during this period.
Long-lasting cellular benefits continue. Telomere length can be retested to confirm gains. Plan next 10-20 day cycle. Most protocols call for 2-3 cycles per year.
What to Expect
Days 1 to 3 (Loading Phase): Telomerase upregulation starts at the cellular level, but nothing is visible or measurable yet. The plasma half-life sits around 30 minutes, so daily injections maintain exposure through repeated hits rather than continuous blood levels. Some users notice slightly faster sleep onset by night 2 or 3. Most feel nothing.
Days 4 to 7 (Early Response Window): Pineal melatonin production begins normalizing. Goncharova's primate data [4] confirmed epithalon restores circadian melatonin rhythms. Sleep improvement is the most commonly reported effect by this point. Deeper sleep, fewer awakenings, better mornings. A subset of users notice a mild mood lift and increased daytime energy. Vivid dreams hit a minority; mild drowsiness after the evening injection is also melatonin-related and typically fades.
Days 8 to 14 (Mid/Late Cycle): Cumulative telomerase activation continues. Whether 10 to 14 days of subcutaneous injection produces measurable telomere elongation in a living human remains unknown. Sleep benefits solidify. General well-being improves. Some users report better skin, though it's hard to separate that from sleeping well.
Weeks 3 to 12 (Post-Cycle Persistence): No injections. Telomere gains, if they occurred, are maintained since telomeres don't shorten overnight. Melatonin normalization often persists 4 to 8 weeks based on the pineal restoration mechanism. Formal duration hasn't been studied in humans. Sleep quality gradually returns to baseline.
Months 4 to 6 (Inter-Cycle Period): Telomere gains hold steady but aren't progressing. Normal age-related attrition resumes. Subjective benefits have mostly faded. Users who post telomere test results after 2 to 3 annual cycles sometimes show modest improvement, but measurement variability makes single data points unreliable. Time to plan the next cycle.
Detailed Timeline: Science vs Community
Telomerase upregulation begins at cellular level. Very short plasma half-life (estimated minutes to ~30 min) means daily dosing maintains exposure via repeated stimulation rather than continuous blood levels. No externally observable changes.
Some users notice slightly improved sleep onset by night 2–3. Most feel nothing yet. Considered the loading window.
Pineal melatonin production may begin normalizing. Animal data (Goncharova et al., PMID 11550036) shows epithalon restores circadian melatonin rhythms in aging primates and rats. Faster biological response than telomere elongation.
Sleep improvement is the most commonly reported effect by this point: deeper sleep, fewer awakenings, waking more refreshed. Subtle mood lift and increased daytime energy reported by a subset. This is the window where most users decide whether "it's working."
Cumulative telomerase activation. Whether 10–14 days of SC injection achieves measurable telomere elongation in a living human is unknown: no human biomarker data published.
Sleep benefits solidify. General sense of well-being and vitality. Some users report improved skin appearance, though hard to separate from sleeping better.
Any telomere gains would be maintained: telomeres do not shorten overnight. Melatonin normalization may persist for weeks based on pineal restoration hypothesis; formal duration not studied in humans.
Sleep benefits often persist 4–8 weeks, then gradually return to baseline. Energy and well-being effects fade over weeks. Users plan next cycle.
Telomere gains, if any occurred, are maintained but not progressing. Normal age-related telomere attrition resumes. No active mechanism.
Most subjective benefits have faded. Some users post telomere test results after 2–3 annual cycles showing modest improvement: anecdotal and subject to high measurement variability.
Pharmacokinetics
Source: Estimated from tetrapeptide class PK data; rapid peptidase degradation (Khavinson et al.); no formal human PK study published
Pharmacokinetics: Active Dose Over Time
t½ = ~30 minutes (plasma)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.
Molecular Profile
Is Epithalon Legal?
Epithalon is classified as a research chemical in the United States. It has no FDA approval for any indication. The FDA placed epithalon on its Category 2 bulk drug substance list, which prohibited US compounding pharmacies from producing it. Its nominators later withdrew it, and FDA's Category 2 page (current as of April 22, 2026) lists it as withdrawn. PCAC discussed epitalon on July 24, 2026. No FDA rule has added it to the 503A bulks list, so compounding pharmacies cannot use it today.
All current US supply is research-grade product, and quality varies. Purity and identity are lab measurements: HPLC purity above 98% and a mass spectrometry reading of the 390.35 Da molecular weight. WADA status: not currently listed, but athletes competing in tested events should verify with their governing body.
This content is for educational and research purposes only. It does not constitute medical advice. Consult a licensed healthcare provider before using any research peptide.
Evidence grade: Small human studies only (Peptide Evidence Gap, October 2026)
Who Should Consider Epithalon
- Adults over 40 seeking proactive aging intervention
- Individuals with shortened telomere length on testing
- Those with disrupted circadian rhythm or poor melatonin production
- Health-optimizers interested in longevity protocols
- Older adults (60+) looking to support cellular repair capacity
Related Peptides
What Changed for Epithalon
- Regulatory
PCAC recommended epitalon for the 503A bulks list on Jul 24, 2026, per a law-firm summary; reported from the meeting; FDA has not posted minutes.
What this does not mean: The vote did not add it to the 503A bulks list. FDA must complete notice-and-comment rulemaking first, and no proposed or final rule exists (Federal Register search, Oct 6, 2026).
Source: FDA meeting page, Pharmacy Compounding Advisory Committee, July 23-24, 2026 (content current as of 08/06/2026) (opens in a new tab) · Reported by Law-firm client alert, "Bulk-list bound? PCAC backs majority of peptides in two-day public meeting" (Jul 27, 2026) (opens in a new tab) · Saved copy
- RegulatoryEffective
Nominators withdrew 12 peptides (GHK-Cu for injectable routes only) from 503A category 2, announced Apr 15, 2026, per the FDA 503A categories list.
What this does not mean: Leaving category 2 does not put a peptide on the 503A bulks list or make it eligible for compounding. That takes FDA rulemaking, and none has been proposed (Federal Register search, Oct 6, 2026).
Also covers: BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, GHK-Cu, LL-37, Dihexa, PEG-MGF, Melanotan II
Source: FDA, Bulk drug substances nominated for use in compounding under section 503A (categories list, updated April 22, 2026; the April 15, 2026 notice version is archived beside it) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
Peptide Schedule Research TeamReviewed Apr 7, 20268 Citations
References
- [1]Epitalon Increases Telomere Length in Human Cell Lines Through Telomerase Upregulation or ALT Activity (2025) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [2]Overview of Epitalon: Highly Bioactive Pineal Tetrapeptide with Promising Properties (Int J Mol Sci 2025) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [3]Epithalon Peptide Induces Telomerase Activity and Telomere Elongation in Human Somatic Cells (Bull Exp Biol Med 2003) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [4]Regulatory effect of Epithalon on production of melatonin and cortisol in old monkeys (Bull Exp Biol Med 2001) (opens in a new tab)PubMed (opens in a new tab)PubMed
Additional References
- Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice (Biogerontology 2003) (opens in a new tab)PubMed 14501183PubMed
- Peptide regulation of gene expression and protein synthesis in bronchial epithelium (Lung 2014) (opens in a new tab)PubMed 25015171PubMed
- PMC12411320 (PMC12411320) (opens in a new tab)PubMed
- FDA briefing document: epitalon-related bulk drug substances, Pharmacy Compounding Advisory Committee, July 23-24, 2026: three human studies of epitalon; seven nominator papers described epithalamin (opens in a new tab)Review
Related Resources
Related Tools
Storage & Stability
Frequently Asked Questions
How popular is Epithalon?
Popular. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
Reddit: Active. Community mentions on Reddit: Active: multiple threads across r/peptides, longevity forum. Open r/peptides (opens in a new tab).
140 papers on PubMed, the US library of medical research. Search them on PubMed (opens in a new tab).
Moderate search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.

